WINNIPEG, MANITOBA--(Marketwire - October 01, 2007) - DiaMedica Inc. (TSX VENTURE: DMA), a drug discovery and development company focused on novel treatments for type 2 diabetes, is pleased to announce exciting results for DM-71 in its proof-of-concept phase II clinical study in type 2 diabetes.
